KAGA FEI Develops Ultra-small Bluetooth Low Energy Module Compatible with Bluetooth 6.0

10.10.2024 16:00:00 CEST | Business Wire | Press release

KAGA FEI Co., Ltd., a global provider of leading short distance wireless modules, announced today the ES4L15BA1 Bluetooth Low Energy module.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241010420482/en/

ES4L15BA1 (Photo: Business Wire)

The module has a built-in antenna and has obtained various certifications. Consequently, it reduces the development time and certification costs for next-generation wireless IoT products such as IoT devices, small medical/healthcare products, and wearable devices that require a compact form factor, enabling faster time-to-market.

The ES4L15BA1 also supports channel sounding for accurate distance measurement, providing further convenience for applications requiring reliable distance information or enhanced security based on device distance information, such as unlocking devices based on their proximity.

Furthermore, it supports PSA^*1 certification, making it easier to develop IoT devices that meet advanced security requirements. Mass production is scheduled to begin in September 2025. KAGA FEI will continue to respond to market needs and expand its product lineup.

Product Features

World’s Smallest Compact Form Factor
The ES4L15BA1 utilizes our proprietary technology to integrate into a 3.25x8.55x1.00mm form factor, achieving the world’s smallest size as an antenna-integrated module compatible with Bluetooth 6.0.
High Processing Power and Large Memory
The ES4L15BA1 includes an Arm Cortex-M33 processor, RISC-V coprocessor, 1.5MB of non-volatile memory, and 256KB RAM, providing excellent processing performance and high processing efficiency.
Built-in Antenna and Pre-Certified
Features a built-in antenna, eliminating the need for antenna design. It has obtained Bluetooth qualification and certifications for Radio Law MIC (Japan), FCC (USA), and ISED (Canada), reducing time and costs. In addition, it supports Bluetooth SIG qualification for the latest Bluetooth 6.0 standard, which enables channel sounding function for accurate distance measurement.

Product Availability

Sample	: February 2025
Start of mass production	: September 2025

About Trademarks

The product names and other proper nouns mentioned herein are trademarks or registered trademarks of their respective companies.

*1. PSA (Platform Security Architecture): PSA is a certification scheme led by Arm. Level 3 is the highest level of certification for protecting IoT devices from physical and software attacks.

KAGA FEI website

https://www.kagafei.com/jp/eng/

Disclaimer

Product specifications, service content, etc. stated in the news release are as of the date of announcement and is subject to change without notice.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241010420482/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release

In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release

IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom